

Citations

1. Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998.
2. WHO. *Fructus silybi mariae*. WHO Monographs on Selected Medicinal Plants. 2 vol. Geneva: World Health Organization; 2002:300-316.
3. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (*Silybum marianum*) for the therapy of liver disease. *Am J Gastroenterol* 1998;93:139-143.
4. Rambaldi A, Jacobs B, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. *Cochrane Database Syst Rev* 2005:CD003620.
5. Ladas EJ, Kelly KM. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? *J Altern Complement Med* 2003;9:411-416.
6. Brinker F. St. Mary's milk thistle: a heavenly mark on a healing herb. *Complex Herbs — Complete Medicines*. Sandy, Ore: Eclectic Medical Publications; 2004:392-417.
7. Enjalbert F, Rapior S, Nougulier-Soule J et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. *J Toxicol Clin Toxicol* 2002;40:715-757.
8. Muriel P, Mourelle M. Prevention by silymarin of membrane alterations in acute CCl₄ liver damage. *J Appl Toxicol* 1990;10:275-279.
9. Chrungoo VJ, Singh K, Singh J. Silymarin-mediated differential modulation of toxicity induced by carbon tetrachloride, paracetamol and d-galactosamine in freshly isolated rat hepatocytes. *Indian J Exp Biol* 1997;35:611-617.
10. Favari L, Perez-Alvarez V. Comparative effects of colchicine and silymarin on CCl₄-chronic liver damage in rats. *Arch Med Res* 1997;28:11-17.
11. Mourelle M, Muriel P, Favari L, Franco T. Prevention of CCl₄-induced liver cirrhosis by silymarin. *Fundam Clin Pharmacol* 1989;3:183-191.
12. Davila JC, Lenherr A, Acosta D. Protective effect of flavonoids on drug-induced hepatotoxicity in vitro. *Toxicology* 1989;57:267-286.
13. Vinh PQ, Sugie S, Tanaka T et al. Chemopreventive effects of a flavonoid antioxidant silymarin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. *Jpn J Cancer Res* 2002;93:42-49.
14. Shalan MG, Mostafa MS, Hassouna MM et al. Amelioration of lead toxicity on rat liver with vitamin C and silymarin supplements. *Toxicology* 2005;206:1-15.
15. Mourelle M, Favari L, Amezcua JL. Protection against thallium hepatotoxicity by silymarin. *J Appl Toxicol* 1988;8:351-354.
16. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. *Biol Res* 1994;27:105-112.
17. Singh RP, Agarwal R. A cancer chemopreventive agent, silibinin, targets mitogenic and survival signaling in prostate cancer. *Mutat Res* 2004;555:21-32.
18. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. *Antioxid Redox Signal* 2002;4:655-663.
19. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. *BioDrugs* 2001;15:465-489.
20. Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. *Clin Drug Invest* 2002;22:51-65.
21. Mills S, Bone K. *Principles and Practice of Phytotherapy*. Edinburgh: Churchill Livingstone; 2000.
22. McKenna D, Jones K, Hughes K, Humphrey S. Milk thistle. *Botanical Medicines*. 2nd ed. Binghamton, NY: Haworth Press; 2002:765-808.
23. Piscitelli SC, Formentini E, Burstein AH et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. *Pharmacotherapy* 2002;22:551-556.
24. DiCenzo R, Shelton M, Jordan K et al. Coadministration of milk thistle and indinavir in healthy subjects. *Pharmacotherapy* 2003;23:866-870.
25. Kim DH, Jin YH, Park JB, Kobashi K. Silymarin and its components are inhibitors of beta-glucuronidase. *Biol Pharm Bull* 1994;17:443-445.
26. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. *Carcinogenesis* 1999;20:2101-2108.
27. Barzagli N, Crema F, Gatti G et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. *Eur J Drug Metab Pharmacokinet* 1990;15:333-338.
28. Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. *Int J Clin Pharmacol Ther Toxicol* 1992;30:134-138.

Citations and Reference Literature: Milk Thistle

29. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). *Altern Med Rev* 2005;10:193-203.
30. He J, Hou S-X, Feng J-F, Cai B-Q. [Effect of particle size on oral absorption of silymarin-loaded solid lipid nanoparticles]. *Zhongguo Zhong Yao Za Zhi* 2005;30:1651-1653.
31. El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. *Int J Pharm* 2005;308:140-148.
32. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. *Pharmacol Toxicol* 2000;86:250-256.
33. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. *Phytomedicine* 2000;7:273-282.
34. Venkataramanan R, Ramachandran V, Komoroski BJ et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. *Drug Metab Dispos* 2000;28:1270-1273.
35. Zuber R, Modriansky M, Dvorak Z et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. *Phytother Res* 2002;16:632-638.
36. Raucy J. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. *Drug Metab Dispos* 2003;31:533-539.
37. Patel J, Buddha B, Dey S et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. *Am J Ther* 2004;11:262-277.
38. Sridar C, Goosen TC, Kent UM et al. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. *Drug Metab Dispos* 2004;32:587-594.
39. Tasduq S, Peerzada K, Koul S et al. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. *Hepatol Res* 2005;31:132-135.
40. Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. *Arzneimittelforschung* 2004;54:109-113.
41. Gurley BJ, Gardner SF, Hubbard MA et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto. *Clin Pharmacol Ther* 2004;76:428-440.
42. Van Erp NPH, Baker SD, Zhao M et al. Effect of milk thistle (*Silybum marianum*) on the pharmacokinetics of irinotecan. *Clin Cancer Res* 2005;11:7800-7806.
43. Chrungoo VJ, Reen RK, Singh K, Singh J. Effects of silymarin on UDP-glucuronic acid and glucuronidation activity in the rat isolated hepatocytes and liver in relation to D-galactosamine toxicity. *Indian J Exp Biol* 1997;35:256-263.
44. Bartholomaeus AR, Bolton R, Ahokas JT. Inhibition of rat liver cytosolic glutathione S-transferase by silybin. *Xenobiotica* 1994;24:17-24.
45. Tager M, Dietzmann J, Thiel U et al. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin. *Free Radic Res* 2001;34:137-151.
46. Zi X, Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. *Biochem Biophys Res Commun* 1999;263:528-536.
47. Mallikarjuna G, Dhanalakshmi S, Singh RP et al. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. *Cancer Res* 2004;64:6349-6356.
48. Zhou S, Lim L, Chowbay B. Herbal modulation of P-glycoprotein. *Drug Metab Rev* 2004;36:57-104.
49. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. *J Pharmacol Exp Ther* 2003;304:1258-1267.
50. Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. *Pharm Res* 2003;20:1184-1191.
51. Nguyen H, Zhang S, Morris M. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. *J Pharm Sci* 2003;92:250-257.
52. Maitrejean M, Comte G, Barron D et al. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. *Bioorg Med Chem Lett* 2000;10:157-160.
53. Boumendjel A, Di Pietro A, Dumontet C, Barron D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. *Med Res Rev* 2002;22:512-529.
54. Perez-Victoria JM, Perez-Victoria FJ, Conseil G et al. High-affinity binding of silybin derivatives to the nucleotide-binding domain of a *Leishmania tropica* P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin. *Antimicrob Agents Chemother* 2001;45:439-446.
55. Zhang S, Yang X, Morris M. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. *Pharm Res* 2004;21:1263-1273.

Citations and Reference Literature: Milk Thistle

56. Gurley B, Barone GW, Williams DK et al. Effect of milk thistle (*Silybum marianum*) and black cohosh (*Cimicifuga racemosa*) supplementation on digoxin pharmacokinetics in humans. *Drug Metab Dispos* 2005;34:69-74.
57. Bokemeyer C, Fels LM, Dunn T et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. *Br J Cancer* 1996;74:2036-2041.
58. Gaedeke J, Fels LM, Bokemeyer C et al. Cisplatin nephrotoxicity and protection by silibinin. *Nephrol Dial Transplant* 1996;11:55-62.
59. Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. *Evid Based Complement Alternat Med* 2005;2:383-386.
60. Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. *Oncol Rep* 2004;11:493-499.
61. Scambia G, De Vincenzo R, Ranelletti FO et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. *Eur J Cancer* 1996;32A:877-882.
62. Giacomelli S, Gallo D, Apollonio P et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. *Life Sci* 2002;70:1447-1459.
63. Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. *Int J Cancer* 2003;106:699-705.
64. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. *Cancer Res* 2000;60:5617-5620.
65. Thelen P, Wuttke W, Jarry H et al. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. *J Urol* 2004;171:1934-1938.
66. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. *Curr Cancer Drug Targets* 2004;4:1-11.
67. Tyagi A, Bhatia N, Condon MS et al. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. *Prostate* 2002;53:211-217.
68. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNF α -induced activation of NF- κ B and sensitizes human prostate carcinoma DU145 cells to TNF α -induced apoptosis. *Oncogene* 2002;21:1759-1767.
69. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. *Prostate* 2001;46:98-107.
70. Chlopickova S, Psotova J, Miketova P, Simanek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. *Phytother Res* 2004;18:107-110.
71. Psotova J, Chlopickova S, Grambal F et al. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. *Phytother Res* 2002;16 Suppl 1:S63-67.
72. Tyagi AK, Singh RP, Agarwal C et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. *Clin Cancer Res* 2002;8:3512-3519.
73. Muriel P, Garciapina T, Perez-Alvarez V, Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. *J Appl Toxicol* 1992;12:439-442.
74. Campos R, Garrido A, Guerra R, Valenzuela A. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. *Planta Med* 1989;55:417-419.
75. Neuman M, Cameron R, Haber J et al. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytotoxicity. *Clin Biochem* 1999;32:519-536.
76. Shear NH, Malkiewicz IM, Klein D et al. Acetaminophen-induced toxicity to human epidermoid cell line A431 and hepatoblastoma cell line Hep G2, in vitro, is diminished by silymarin. *Skin Pharmacol* 1995;8:279-291.
77. Mourelle M, Favari L. Silymarin improves metabolism and disposition of aspirin in cirrhotic rats. *Life Sci* 1988;43:201-207.
78. Favari L, Soto C, Mourelle M. Effect of portal vein ligation and silymarin treatment on aspirin metabolism and disposition in rats. *Biopharm Drug Dispos* 1997;18:53-64.
79. Radovanovic D, Jovanovic D, Mihailovic D et al. [Hepatoprotective effects of silymarin in androgenic-anabolic steroid-induced liver damage]. *Med Pregl* 2003;56 Suppl 1:79-83.
80. Fintelmann V. Toxic-metabolic liver damage and its treatment. *Zeitschr Phytother* 1986;3:65-73.
81. Kurz-Dimitrowa D. Preservation of liver function in psychiatric patients receiving long term treatment with psychopharmaceuticals. *Zeitschr Praktin Geriatr* 1971;9:275.
82. Victorrajmohan C, Pradeep K, Karthikeyan S. Influence of silymarin administration on hepatic glutathione-conjugating enzyme system in rats treated with antitubercular drugs. *Drugs R D* 2005;6:395-400.
83. Valenzuela A, Bustamante JC, Videla C, Guerra R. Effect of silybin dihemisuccinate on the ethanol metabolizing systems of the rat liver. *Cell Biochem Funct* 1989;7:173-178.

Citations and Reference Literature: Milk Thistle

84. Valenzuela A, Lagos C, Schmidt K, Videla LA. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. *Biochem Pharmacol* 1985;34:2209-2212.
85. Song Z, Deaciuc I, Song M et al. Silymarin protects against acute ethanol-induced hepatotoxicity in mice. *Alcohol Clin Exp Res* 2006;30:407-413.
86. Edwards J, Grange LL, Wang M, Reyes E. Fetoprotectivity of the flavanolignan compound siliphos against ethanol-induced toxicity. *Phytother Res* 2000;14:517-521.
87. Feher J, Deak G, Muzes G et al. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases]. *Orv Hetil* 1989;130:2723-2727.
88. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol* 1989;9:105-113.
89. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver: a double-blind controlled study. *Scand J Gastroenterol* 1982;17:517-521.
90. Fintelmann V, Albert A. The therapeutic activity of Legalon in toxic hepatic disorders demonstrated in a double-blind trial. *Therapiewoche* 1980;30:5589-5594.
91. Janiak B. [Depression of microsomal activity in the liver of mice following single administration of halothane and its influenciability by silybin]. *Anaesthesist* 1974;23:389-393.
92. Siegers CP, Fruhling A, Younes M. Influence of dithiocarb. (+)-catechin and silybine on halothane hepatotoxicity in the hypoxic rat model. *Acta Pharmacol Toxicol (Copenh)* 1983;53:125-129.
93. Invernizzi R, Bernuzzi S, Ciani D, Ascari E. Silymarin during maintenance therapy of acute promyelocytic leukemia. *Haematologica* 1993;78:340-341.
94. Fintelmann V. [Serum cholinesterase and other liver enzymes in post-surgical conditions]. *Medizinische Klinik* 1973;68:809-815.
95. Palasciano G, Portincasa P, Palmieri P et al. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long-term treatment with psychotropic drugs. *Curr Ther Res* 1994;55.
96. Saba P, Galeone F, Salvadorini F, Guarguaglini M. [Therapeutic action of silymarin on chronic hepatopathies caused by psychopharmaceuticals]. *Gazzetta Medica Italiana* 1976;135:236-251.
97. He Q, Kim J, Sharma RP. Silymarin protects against liver damage in BALB/c mice exposed to fumonisin B1 despite increasing accumulation of free sphingoid bases. *Toxicol Sci* 2004;80:335-342.
98. Von Schonfeld J, Weisbrod B, Muller MK. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. *Cell Mol Life Sci* 1997;53:917-920.
99. Soto C, Mena R, Luna J et al. Silymarin induces recovery of pancreatic function after alloxan damage in rats. *Life Sci* 2004;75:2167-2180.
100. Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Stimulatory effects of silibinin and silicristin from the milk thistle *Silybum marianum* on kidney cells. *J Pharmacol Exp Ther* 1999;290:1375-1383.
101. Soto CP, Perez BL, Favari LP, Reyes JL. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol* 1998;119:125-129.
102. Soto C, Recoba R, Barron H et al. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. *Comp Biochem Physiol C Toxicol Pharmacol* 2003;136:205-212.
103. Velussi M, Cernigoi AM, De Monte A et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. *J Hepatol* 1997;26:871-879.
104. Chon S-K, Kim N-S. Evaluation of silymarin in the treatment on asymptomatic *Giardia* infections in dogs. *Parasitol Res* 2005;97:445-451.
105. Seidlova-Wuttke D, Becker T, Christoffel V et al. Silymarin is a selective estrogen receptor beta (ER β) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. *J Steroid Biochem Mol Biol* 2003;86:179-188.
106. Adverse Drug Reactions Advisory Committee. An adverse reaction to the herbal medication milk thistle (*Silybum marianum*). *Med J Aust* 1999;170:218-219.
107. Allain H, Schuck S, Lebreton S et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. *Dement Geriatr Cogn Disord* 1999;10:181-185.